Study register · detail
Clear benefit
GRADE
High
97 citations
Samplen = 34.653 Pat.
DurationCross-sectional
EndpointPsychosis / schizotypal…
Blindingn.a.
DesignQuerschnittstudie (repräsentative Bevölkerungsstichprobe)
Key finding
Cannabis use is dose-dependently associated with significantly increased odds of psychosis and schizotypal personality disorder.
Summary
NESARC study (n=34.653, nationally representative US sample, 2004–2005); cannabis use dose-dependently associated with psychosis risk: lifetime use OR=1,27 (95% CI 1,03–1,57), cannabis abuse OR=1,79 (95% CI 1,35–2,38), cannabis dependence OR=3,69 (95% CI 2,49–5,47); schizotypal personality disorder also dose-dependently increased (lifetime use OR=2,02; dependence OR=7,32, 95% CI 5,51–9,72).
P
PopulationAdults from a representative US population sample, n=34.653 (NESARC Wave 2, 2004–2005)
I
InterventionLifetime cannabis use (lifetime prevalence, cannabis abuse, cannabis dependence)
O
OutcomeDose-dependent association between cannabis use and psychosis (OR=1,27 for lifetime use; OR=1,79 for abuse; OR=3,69 for dependence) as well as schizotypal personality disorder (OR=2,02 / 2,83 / 7,32)
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
<h4>Background</h4>Studies to date showing an association between cannabis use and schizophrenia-spectrum disorders are of relatively small sample sizes with limitations in generalizability. The present study addresses this gap by examining the relationship between cannabis use and psychotic-like symptoms in a large representative community sample.<h4>Method</h4>Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, Wave 2), a large, nationally representative sample of 34,653 adults from the United States population. We evaluated the association between lifetime cannabis use, psychosis, and schizotypal personality features.<h4>Results</h4>The prevalence of psychosis and schizotypal personality disorder increased significantly with greater cannabis use in a dose-dependent manner. The associations between cannabis use and psychosis were 1.27 (95% CI 1.03-1.57) for lifetime cannabis use, 1.79 (95% CI 1.35-2.38) for lifetime cannabis abuse, and 3.69 (95% CI 2.49-5.47) for lifetime cannabis dependence. There was a similar dose-response relationship between the extent of cannabis use and schizotypal personality disorder (OR=2.02 for lifetime cannabis use, 95% CI 1.69-2.42; OR=2.83 for lifetime cannabis abuse, 95% CI 2.33-2.43; OR=7.32 for lifetime cannabis dependence, 95% CI 5.51-9.72). Likelihood of individual schizotypal features increased significantly with increased extent of cannabis use in a dose-dependent manner.<h4>Conclusion</h4>This is the first population-based study to examine the association between lifetime cannabis use, psychosis, and schizotypal personality traits. These results add to evidence that cannabis use may be a risk factor for psychosis liability.
The impediment to action advances action.